Unicycive Therapeutics shares are trading lower after the company provided an update concerning its marketing application for lanthanum dioxycarbonate for hyperphosphatemia in chronic kidney disease patients on dialysis.
Portfolio Pulse from Benzinga Newsdesk
Unicycive Therapeutics has provided an update on its marketing application for lanthanum dioxycarbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis. Following the update, the company's shares are trading lower.
June 30, 2023 | 8:30 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Unicycive Therapeutics' shares are trading lower after the company updated its marketing application for lanthanum dioxycarbonate.
The company's shares are trading lower following the update on its marketing application. This suggests that the market may have reacted negatively to the news, potentially due to concerns about the product's approval or commercial success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100